Recombinant porcine factor VIII use in bleed treatment in non-severe haemophilia A inhibitor patients: Dosing strategies and efficacy

被引：0
|
作者：
Ellsworth, Patrick [1 ,2 ]
Chen, Sheh-Li [3 ]
Key, Nigel [1 ]
Abajas, Yasmina [2 ]
Ma, Alice [1 ]
机构：
[1] Univ N Carolina, Dept Med, Div Hematol Oncol, Houpt Bldg,CB 7305,170 Manning Dr,3rd Floor, Chapel Hill, NC 27599 USA
[2] Univ N Carolina, Dept Pediat, Div Pediat Hematol Oncol, Chapel Hill, NC 27599 USA
[3] Univ N Carolina, Eshelman Sch Pharm, Chapel Hill, NC 27599 USA
来源：
HAEMOPHILIA | 2021年 / 27卷 / 01期
关键词：
OBI-1; SEQUENCE; SAFETY;
D O I：
10.1111/hae.14111
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E147 / E150
页数：4
相关论文
共 50 条
  • [31] Desmopressin treatment combined with clotting factor VIII concentrates in patients with non-severe haemophilia A: protocol for a multicentre single-armed trial, the DAVID study
    Schutte, Lisette M.
    Cnossen, Marjon H.
    van Hest, Reinier M.
    Driessens, Mariette H. E.
    Fijnvandraat, Karin
    Polinder, Suzanne
    Beckers, Erik A. M.
    Coppens, Michiel
    Eikenboom, Jeroen
    Gorkom, Britta A. P. Laros-van
    Meijer, Karina
    Nieuwenhuizen, Laurens
    Mauser-Bunschoten, Evelien P.
    Leebeek, Frank W. G.
    Mathot, Ron A. A.
    Kruip, Marieke J. H. A.
    BMJ OPEN, 2019, 9 (04):
  • [32] Efficacy and inhibitor development in previously treated patients with haemophilia A switched to a B domain-deleted recombinant factor VIII
    Gringeri, A
    Tagliaferri, A
    Tagariello, G
    Morfini, M
    Santagostino, E
    Mannucci, P
    BRITISH JOURNAL OF HAEMATOLOGY, 2004, 126 (03) : 398 - 404
  • [33] Clinical and laboratory data of safety, efficacy of a recombinant factor VIII concentrate in patients with severe haemophilia a in a private practice CCC
    KoehlerVajta, K.
    Froesner, G.
    Zachoval, R.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 : 220 - 221
  • [34] Treatment of serious bleeds with an antihaemophilic factor VIII (recombinant), porcine sequence (OBI-1) in patients with acquired haemophilia A
    Kruse-Jarres, R.
    St-Louis, J.
    Greist, A.
    Shapiro, A.
    Smith, H.
    Chowdary, P.
    Drebes, A.
    Gomperts, E.
    Bourgeois, C.
    Mo, M.
    Novack, A.
    Farin, H.
    Ewenstein, B.
    HAEMOPHILIA, 2015, 21 : 62 - 62
  • [35] Update of the risk of inhibitor occurrence at first treatment by a Factor VIII concentrate in severe haemophilia A
    Chambost, H.
    Guillaume, Y.
    Falaise, C.
    Roux, C.
    Monpoux, F.
    REVUE D ONCOLOGIE HEMATOLOGIE PEDIATRIQUE, 2015, 3 (02): : 78 - 87
  • [36] Efficacy and Safety of a Recombinant von Willebrand Factor for Bleed Treatment in Patients with Severe von Willebrand Disease
    Gill, J.
    Castaman, G.
    Windyga, J.
    Kouides, P.
    Ragni, M.
    Leebeek, F.
    HAEMOPHILIA, 2015, 21 (03) : E263 - E263
  • [37] Factor VIII gene (F8) mutation and inhibitor development in non-severe hemophilia A
    De Groot-Eckhardt, C. L.
    Van Velzen, A. S.
    Peters, M.
    Peerlinck, K.
    Oldenburg, J.
    Santagostino, E.
    Astermark, J.
    Van Heerde, W. L.
    Hermans, C.
    Morfini, M.
    Castaman, G.
    Haya, S.
    McRae, S.
    Reitter-Pfoertner, S. E.
    Kamphuisen, P. W.
    Van der Bom, J. G.
    Fijnvandraat, K. J.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 33 - 33
  • [38] Immune system polymorphisms and factor VIII inhibitor formation in Brazilian haemophilia A severe patients
    Agostini, D.
    Rosset, C.
    Botton, M. R.
    Kappel, D. B.
    Vieira, I. A.
    Gorziza, R. P.
    Salzano, F. M.
    Bandinelli, E.
    HAEMOPHILIA, 2012, 18 (06) : e416 - e418
  • [39] Efficacy and safety of recombinant porcine factor VIII in Japanese patients with acquired hemophilia A
    Seki, Yoshinobu
    Ogawa, Yoshiyuki
    Kikuchi, Takahide
    Sakaida, Emiko
    Mizuta, Yuki
    Kitagawa, Tadayuki
    Takemura, Kazuhiko
    Miyaguchi, Yasuo
    Nogami, Keiji
    Matsushita, Tadashi
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2024, 120 (04) : 482 - 491
  • [40] Haemophilia A mutations in patients with non-severe phenotype associated with a discrepancy between one-stage and chromogenic factor VIII activity assays
    Pavlova, Anna
    Delev, Daniel
    Pezeshkpoor, Behnaz
    Mueller, Jens
    Oldenburg, Johannes
    THROMBOSIS AND HAEMOSTASIS, 2014, 111 (05) : 851 - 861
12345